Abbott Laboratories $ABT Shares Purchased by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 398.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,186 shares of the healthcare product maker’s stock after acquiring an additional 12,140 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in Abbott Laboratories were worth $1,378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of ABT. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth $25,000. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ABT. Piper Sandler restated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Bank of America reduced their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Stock Performance

NYSE:ABT traded down $2.67 during mid-day trading on Tuesday, reaching $105.66. 11,397,135 shares of the stock were exchanged, compared to its average volume of 11,627,073. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a 50 day simple moving average of $105.04 and a 200-day simple moving average of $99.95. The stock has a market capitalization of $182.82 billion, a P/E ratio of 34.19, a P/E/G ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the company posted $1.26 EPS. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.